BR112015010620A2 - compostos heteroaromáticos e seus usos como ligantes de dopamina d1 - Google Patents
compostos heteroaromáticos e seus usos como ligantes de dopamina d1Info
- Publication number
- BR112015010620A2 BR112015010620A2 BR112015010620A BR112015010620A BR112015010620A2 BR 112015010620 A2 BR112015010620 A2 BR 112015010620A2 BR 112015010620 A BR112015010620 A BR 112015010620A BR 112015010620 A BR112015010620 A BR 112015010620A BR 112015010620 A2 BR112015010620 A2 BR 112015010620A2
- Authority
- BR
- Brazil
- Prior art keywords
- dopamine
- agonists
- ser
- interacting
- heteroaromatic compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
resumo compostos heteroaromáticos e seus usos como ligantes de dopamina d1 a presente invenção proporciona, em parte, compostos da fórmula i: e sais aceitáveis farmaceuticamente dos mesmos e n-óxidos dos mesmos; processos e intermediários para a preparação de; e composições e usos dos mesmos. a presente invenção ainda proporciona agonistas d1 com dessensibilização d1r, agonistas d1 com atividade de recrutamento de ß-arrestina reduzida relativa a dopamina, agonistas d1 interagindo significantemente com o ser 188, mas não significantemente com o ser 202 de um d1r quando se ligando ao d1r, agonistas d1 interagindo em menor intensidade com o asp 103 e interagindo em menor intensidade com o ser 198 de um d1r quando se ligando ao d1r, e seus usos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261723966P | 2012-11-08 | 2012-11-08 | |
US201361881218P | 2013-09-23 | 2013-09-23 | |
PCT/IB2013/059754 WO2014072881A1 (en) | 2012-11-08 | 2013-10-29 | Heteroaromatic compounds and their use as dopamine d1 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015010620A2 true BR112015010620A2 (pt) | 2017-07-11 |
Family
ID=49955423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015010620A BR112015010620A2 (pt) | 2012-11-08 | 2013-10-29 | compostos heteroaromáticos e seus usos como ligantes de dopamina d1 |
Country Status (15)
Country | Link |
---|---|
US (4) | US20150291625A1 (pt) |
EP (2) | EP3323821A1 (pt) |
JP (2) | JP5857168B2 (pt) |
KR (1) | KR20150065191A (pt) |
CN (1) | CN104981472A (pt) |
AU (1) | AU2013343104A1 (pt) |
BR (1) | BR112015010620A2 (pt) |
CA (1) | CA2890009C (pt) |
ES (1) | ES2649144T3 (pt) |
HK (2) | HK1210608A1 (pt) |
IL (1) | IL238240A0 (pt) |
MX (1) | MX2015005812A (pt) |
RU (1) | RU2617842C2 (pt) |
SG (1) | SG11201502763VA (pt) |
WO (1) | WO2014072881A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201500402A1 (ru) | 2012-11-08 | 2016-05-31 | Пфайзер Инк. | Гетероароматические соединения в качестве лигандов допамина d1 |
MX2020013099A (es) * | 2013-06-27 | 2022-07-26 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. |
KR20160142401A (ko) * | 2014-04-25 | 2016-12-12 | 화이자 인코포레이티드 | 도파민 d1 리간드로서 헤테로방향족 화합물 및 이의 용도 |
CR20160494A (es) | 2014-04-25 | 2016-12-20 | Pfizer | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 |
WO2015162518A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
JP6564394B2 (ja) * | 2014-04-28 | 2019-08-21 | ファイザー・インク | 複素環式化合物およびそのドーパミンd1リガンドとしての使用 |
WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
CN105622531A (zh) * | 2015-04-03 | 2016-06-01 | 南京明德新药研发股份有限公司 | 轴手性异构体及其制备方法和制药用途 |
US10207002B2 (en) | 2015-06-26 | 2019-02-19 | Merck Sharp & Dohme Corp. | Sustained release formulation and tablets prepared therefrom |
CN105837503A (zh) * | 2016-05-12 | 2016-08-10 | 蚌埠中实化学技术有限公司 | 一种6-溴喹啉的制备方法 |
CN110218712B (zh) * | 2016-06-02 | 2021-08-03 | 天津科技大学 | 磷脂酶d突变体及其在制备磷脂酸、磷脂酰丝氨酸中的应用 |
EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
TWI820013B (zh) | 2017-01-23 | 2023-11-01 | 美商銳新醫藥公司 | 作為別構shp2抑制劑之雙環化合物 |
MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
DK3717025T3 (da) | 2017-12-01 | 2021-11-22 | UCB Biopharma SRL | Billeddannende midler |
MX2020006273A (es) | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Compuestos policiclicos como inhibidores alostericos de shp2. |
CN113200830B (zh) * | 2021-04-30 | 2022-09-23 | 上海贤鼎生物科技有限公司 | 一种对羟基苯乙酮的合成方法 |
CN118401513A (zh) * | 2022-01-29 | 2024-07-26 | 苏州科睿思制药有限公司 | 他伐帕敦的晶型及其制备方法和用途 |
CN116253756B (zh) * | 2023-05-11 | 2023-07-18 | 北京元延医药科技股份有限公司 | 克立硼罗的制备方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1507009A (en) * | 1924-03-05 | 1924-09-02 | Littleford Brothers | Portable tar and asphalt heater for road maintenance |
US1908176A (en) * | 1929-05-28 | 1933-05-09 | Chemical Foundation Inc | Process of making a purified coal tar ointment |
US2145158A (en) * | 1935-09-04 | 1939-01-24 | Dammann Karl | Method of applying tar or bitumen to road surfaces |
US3617213A (en) * | 1968-12-02 | 1971-11-02 | Robert Curtis Britt | Coal tar methyl naphthalene fraction and diphenyl carrier and dyeing therewith |
US3928579A (en) * | 1974-11-25 | 1975-12-23 | Warner Lambert Co | Process for the purification of coal tar |
US4102995A (en) * | 1976-05-13 | 1978-07-25 | Westwood Pharmaceuticals Inc. | Tar gel formulation |
US4178373A (en) * | 1978-08-21 | 1979-12-11 | William H. Rorer, Inc. | Coal tar gel composition |
DE3402392A1 (de) * | 1984-01-25 | 1985-08-01 | Sandoz-Patent-GmbH, 7850 Lörrach | Neue ergolinderivate, deren herstellung und deren verwendung |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
CN1118598A (zh) * | 1993-03-01 | 1996-03-13 | 默克·夏普-道姆公司 | 吡咯并吡啶衍生物 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
JP4166296B2 (ja) * | 1997-04-25 | 2008-10-15 | 塩野義製薬株式会社 | ドーパミン受容体拮抗作用を有する化合物 |
US5891646A (en) | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
US6528271B1 (en) | 1997-06-05 | 2003-03-04 | Duke University | Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US6689883B1 (en) | 1999-09-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
DK1480647T3 (da) * | 2002-02-15 | 2009-01-26 | Darpharma Inc | Mono-ester eller asymmetrisk substituerede di-ester-prodrugs af dopamin-D1 receptoragonister |
CN101423497A (zh) * | 2002-07-19 | 2009-05-06 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物 |
EP1578420A4 (en) * | 2002-10-22 | 2007-05-09 | Drugabuse Sciences S A S | TREATMENT OF COGNITIVE DISTURBANCES WITH SELECTIVE DOPAMINE D1 RECEPTOR AGONIST |
JP2005104838A (ja) * | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
US20060074102A1 (en) * | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
RU2467007C2 (ru) | 2005-12-21 | 2012-11-20 | Эбботт Лэборетриз | Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv |
CA2648957A1 (en) | 2006-04-15 | 2007-10-25 | Bayer Healthcare Ag | Compounds for treating pulmonary hypertension |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
WO2008020306A2 (en) * | 2006-08-18 | 2008-02-21 | Pfizer Products Inc. | Isoindole derivatives |
WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
WO2008089310A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of obesity |
WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
US7829567B2 (en) | 2007-10-31 | 2010-11-09 | Kaohsiung Medical University | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same |
MX2010006243A (es) | 2007-12-06 | 2010-08-31 | Schering Corp | Moduladores de gamma secretasa. |
EP2257542A1 (en) | 2008-02-29 | 2010-12-08 | Schering Corporation | Gamma secretase modulators for the treatment of alzheimer ' s disease |
GB0811980D0 (en) | 2008-07-07 | 2008-07-30 | Ceramaspeed Ltd | Radiant electric heater |
JP2012502104A (ja) | 2008-09-10 | 2012-01-26 | カリプシス・インコーポレーテッド | 疾患の治療のためのヒスタミン受容体に対するアミノピリミジン阻害剤 |
WO2010131146A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
KR20120018224A (ko) | 2009-06-09 | 2012-02-29 | 아브락시스 바이오사이언스, 엘엘씨 | 헷지호그 신호전달 억제제로서의 이소퀴놀린, 퀴놀린 및 퀴나졸린 유도체 |
PT2512474E (pt) * | 2009-12-16 | 2014-12-23 | Pfizer | Derivados de ácido hidroxâmico n-ligado úteis como agentes antibacterianos |
EA201500402A1 (ru) | 2012-11-08 | 2016-05-31 | Пфайзер Инк. | Гетероароматические соединения в качестве лигандов допамина d1 |
MX2020013099A (es) | 2013-06-27 | 2022-07-26 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. |
-
2013
- 2013-10-29 US US14/435,954 patent/US20150291625A1/en not_active Abandoned
- 2013-10-29 CA CA2890009A patent/CA2890009C/en not_active Expired - Fee Related
- 2013-10-29 ES ES13820922.6T patent/ES2649144T3/es active Active
- 2013-10-29 JP JP2015540248A patent/JP5857168B2/ja active Active
- 2013-10-29 KR KR1020157011953A patent/KR20150065191A/ko active IP Right Grant
- 2013-10-29 AU AU2013343104A patent/AU2013343104A1/en not_active Abandoned
- 2013-10-29 EP EP17191598.6A patent/EP3323821A1/en not_active Withdrawn
- 2013-10-29 CN CN201380058426.6A patent/CN104981472A/zh active Pending
- 2013-10-29 RU RU2015115400A patent/RU2617842C2/ru not_active IP Right Cessation
- 2013-10-29 SG SG11201502763VA patent/SG11201502763VA/en unknown
- 2013-10-29 WO PCT/IB2013/059754 patent/WO2014072881A1/en active Application Filing
- 2013-10-29 BR BR112015010620A patent/BR112015010620A2/pt not_active IP Right Cessation
- 2013-10-29 MX MX2015005812A patent/MX2015005812A/es unknown
- 2013-10-29 EP EP13820922.6A patent/EP2917219B1/en active Active
-
2015
- 2015-04-12 IL IL238240A patent/IL238240A0/en unknown
- 2015-08-07 US US14/820,611 patent/US9617275B2/en active Active
- 2015-11-10 JP JP2015220278A patent/JP2016053072A/ja active Pending
- 2015-11-17 HK HK15111322.9A patent/HK1210608A1/xx unknown
-
2017
- 2017-03-01 US US15/446,369 patent/US20170165270A1/en not_active Abandoned
-
2018
- 2018-03-16 US US15/923,285 patent/US20180200253A1/en not_active Abandoned
- 2018-11-21 HK HK18114904.6A patent/HK1255830A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2016053072A (ja) | 2016-04-14 |
US20150344490A1 (en) | 2015-12-03 |
HK1255830A1 (zh) | 2019-08-30 |
MX2015005812A (es) | 2015-09-23 |
EP2917219B1 (en) | 2017-09-27 |
RU2015115400A (ru) | 2016-12-27 |
CA2890009A1 (en) | 2014-05-15 |
US20170165270A1 (en) | 2017-06-15 |
RU2617842C2 (ru) | 2017-04-28 |
ES2649144T3 (es) | 2018-01-10 |
AU2013343104A1 (en) | 2015-04-23 |
IL238240A0 (en) | 2015-06-30 |
CA2890009C (en) | 2017-11-28 |
SG11201502763VA (en) | 2015-05-28 |
EP3323821A1 (en) | 2018-05-23 |
KR20150065191A (ko) | 2015-06-12 |
JP5857168B2 (ja) | 2016-02-10 |
JP2015535275A (ja) | 2015-12-10 |
CN104981472A (zh) | 2015-10-14 |
US20150291625A1 (en) | 2015-10-15 |
US20180200253A1 (en) | 2018-07-19 |
WO2014072881A1 (en) | 2014-05-15 |
EP2917219A1 (en) | 2015-09-16 |
HK1210608A1 (en) | 2016-04-29 |
US9617275B2 (en) | 2017-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015010620A2 (pt) | compostos heteroaromáticos e seus usos como ligantes de dopamina d1 | |
BR112017004741A2 (pt) | compostos e composições como inibidores da raf quinase | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
BR112016008632A8 (pt) | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica | |
BR112012030184A2 (pt) | derivados de ácido piridinilcarboxílico como fungicidas | |
BR112016006651B8 (pt) | compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos | |
MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
BR112017002221A2 (pt) | 2-(morfolin-4-il)-1,7-naftiridinas | |
BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
MX2020003112A (es) | Composiciones de biguanida y metodos para tratar trastornos metabolicos. | |
BR112016018604A2 (pt) | Benzimidazol-2-aminas como inibidores de midh1 | |
BR112015008325A2 (pt) | compostos antivirais contra o rsv | |
BR112013004231A2 (pt) | derivados de heteroariliperidina e piperazina como fungicidas | |
BR112014022000A2 (pt) | compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende | |
BR112015021524A2 (pt) | derivados de sulfonil quinolina e usos dos mesmos | |
PH12015500746A1 (en) | Benzamides | |
PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
BR112014031091A2 (pt) | Derivados de piperidina para agonista de gpr119 | |
BR112013000059A2 (pt) | derivados de piperidina e seus usos para o tratamento de distúrbios metabólicos | |
BR112015004529A8 (pt) | alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende | |
BR112014003587A8 (pt) | Derivados de 5-flúor-4-imino-3-(substituído)-3,4-dihidropirimidin-2(1h)ona, composição e método para controle ou prevenção de um patógeno fúngico | |
BR112013026397A2 (pt) | Compostos cromenona como inibidores de pi 3-cinase para o tratamento de câncer | |
BR112015001697A2 (pt) | formulações de clomazona | |
BR112014030720A8 (pt) | composto, composição farmacêutica e usos de inibidores de fbx03 | |
BR112014027047A2 (pt) | nova formulação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2485 DE 21-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |